140 related articles for article (PubMed ID: 35205332)
1. Characterization of the Genomic Landscape in Cervical Cancer by Next Generation Sequencing.
Qiu L; Feng H; Yu H; Li M; You Y; Zhu S; Yang W; Jiang H; Wu X
Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205332
[TBL] [Abstract][Full Text] [Related]
2. Efficient mutation screening for cervical cancers from circulating tumor DNA in blood.
Lee SY; Chae DK; Lee SH; Lim Y; An J; Chae CH; Kim BC; Bhak J; Bolser D; Cho DH
BMC Cancer; 2020 Jul; 20(1):694. PubMed ID: 32718341
[TBL] [Abstract][Full Text] [Related]
3. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
[TBL] [Abstract][Full Text] [Related]
4. Identifying Genomic Alterations in Patients With Stage IV Breast Cancer Using MammaSeq: An International Collaborative Study.
Shah OS; Soran A; Sahin M; Knapick BA; Ugras S; Celik E; Lucas PC; Lee AV
Clin Breast Cancer; 2021 Jun; 21(3):210-217. PubMed ID: 33191115
[TBL] [Abstract][Full Text] [Related]
5. Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population.
Huang Q; Zhou Y; Wang B; Zhao Y; Zhang F; Ding B
BMC Med Genomics; 2022 Jul; 15(1):146. PubMed ID: 35778737
[TBL] [Abstract][Full Text] [Related]
6. Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
Lou H; Villagran G; Boland JF; Im KM; Polo S; Zhou W; Odey U; Juárez-Torres E; Medina-Martínez I; Roman-Basaure E; Mitchell J; Roberson D; Sawitzke J; Garland L; Rodríguez-Herrera M; Wells D; Troyer J; Pinto FC; Bass S; Zhang X; Castillo M; Gold B; Morales H; Yeager M; Berumen J; Alvirez E; Gharzouzi E; Dean M
Clin Cancer Res; 2015 Dec; 21(23):5360-70. PubMed ID: 26080840
[TBL] [Abstract][Full Text] [Related]
7. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer.
Jiang W; He T; Liu S; Zheng Y; Xiang L; Pei X; Wang Z; Yang H
J Hematol Oncol; 2018 Dec; 11(1):139. PubMed ID: 30547809
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
Akahane T; Kanomata N; Harada O; Yamashita T; Kurebayashi J; Tanimoto A; Moriya T
BMC Cancer; 2020 Oct; 20(1):944. PubMed ID: 33004031
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing-Based Detection of Germline Copy Number Variations in BRCA1/BRCA2: Validation of a One-Step Diagnostic Workflow.
Schmidt AY; Hansen TVO; Ahlborn LB; Jønson L; Yde CW; Nielsen FC
J Mol Diagn; 2017 Nov; 19(6):809-816. PubMed ID: 28822785
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
[TBL] [Abstract][Full Text] [Related]
11. Targeting of β-Catenin Reverses Radioresistance of Cervical Cancer with the
Jiang W; Wu Y; He T; Zhu H; Ke G; Xiang L; Yang H
Mol Cancer Ther; 2020 Feb; 19(2):337-347. PubMed ID: 31666350
[TBL] [Abstract][Full Text] [Related]
12. Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation.
Wei Y; Wei C; Chen L; Liu N; Ou Q; Yin JC; Pang J; Fang Z; Wu X; Wang X; Mu D; Shao Y; Yu J; Yuan S
Cancer Res Treat; 2022 Oct; 54(4):1209-1218. PubMed ID: 35038823
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Molecular Characterization of Chinese Patients with Glioma by Extensive Next-Generation Sequencing Panel Analysis.
Zeng C; Wang J; Li M; Wang H; Lou F; Cao S; Lu C
Cancer Manag Res; 2021; 13():3573-3588. PubMed ID: 33953611
[TBL] [Abstract][Full Text] [Related]
14. Landscape of genomic alterations in cervical carcinomas.
Ojesina AI; Lichtenstein L; Freeman SS; Pedamallu CS; Imaz-Rosshandler I; Pugh TJ; Cherniack AD; Ambrogio L; Cibulskis K; Bertelsen B; Romero-Cordoba S; Treviño V; Vazquez-Santillan K; Guadarrama AS; Wright AA; Rosenberg MW; Duke F; Kaplan B; Wang R; Nickerson E; Walline HM; Lawrence MS; Stewart C; Carter SL; McKenna A; Rodriguez-Sanchez IP; Espinosa-Castilla M; Woie K; Bjorge L; Wik E; Halle MK; Hoivik EA; Krakstad C; Gabiño NB; Gómez-Macías GS; Valdez-Chapa LD; Garza-Rodríguez ML; Maytorena G; Vazquez J; Rodea C; Cravioto A; Cortes ML; Greulich H; Crum CP; Neuberg DS; Hidalgo-Miranda A; Escareno CR; Akslen LA; Carey TE; Vintermyr OK; Gabriel SB; Barrera-Saldaña HA; Melendez-Zajgla J; Getz G; Salvesen HB; Meyerson M
Nature; 2014 Feb; 506(7488):371-5. PubMed ID: 24390348
[TBL] [Abstract][Full Text] [Related]
15. Next generation sequencing of cervical high grade dysplasia and invasive squamous cell carcinoma: A case study.
Vormittag-Nocito E; Groth JV; Mohapatra G
Pathol Res Pract; 2020 Apr; 216(4):152863. PubMed ID: 32098697
[TBL] [Abstract][Full Text] [Related]
16. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
[TBL] [Abstract][Full Text] [Related]
17. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
18. Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl S; Popovic M; de la Rochefordiere A; Girard E; Dureau S; Mandic A; Koprivsek K; Samet N; Craina M; Margan M; Samuels S; Zijlmans H; Kenter G; Hillemanns P; Dema S; Dema A; Malenkovic G; Djuran B; Floquet A; Garbay D; Guyon F; Colombo PE; Fabbro M; Kerr C; Ngo C; Lecuru F; Campo ERD; Coutant C; Marchal F; Mesgouez-Nebout N; Fourchotte V; Feron JG; Morice P; Deutsch E; Wimberger P; Classe JM; Gleeson N; von der Leyen H; Minsat M; Dubot C; Gestraud P; Kereszt A; Nagy I; Balint B; Berns E; Jordanova E; Saint-Jorre N; Savignoni A; Servant N; Hupe P; de Koning L; Fumoleau P; Rouzier R; Kamal M
EBioMedicine; 2019 May; 43():253-260. PubMed ID: 30952619
[TBL] [Abstract][Full Text] [Related]
19. The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer.
Jiang W; Ouyang X; Ji Z; Shi W; Wu Y; Yao Q; Wang Y; Yang W; Xiang L; Yang H
Cancer Lett; 2023 Mar; 556():216064. PubMed ID: 36646410
[TBL] [Abstract][Full Text] [Related]
20. Driver gene mutations in micro-invasive cervical squamous cancers have no prognostic significance.
Kashofer K; Regauer S; Reich O; Petru E; Winter E
Gynecol Oncol; 2022 Apr; 165(1):121-128. PubMed ID: 35101299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
